RCT | Cabozantinib addition to nivolumab and ipilimumab extends progression-free survival in renal-cell carcinoma

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Cabozantinib in Renal-Cell Carcinoma – NEJM Resident 360

Commentary on Twitter

Clinical Pearls & Morning Reports: Cabozantinib in Renal-Cell Carcinoma. How did the addition of cabozantinib to nivolumab and ipilimumab affect outcomes in the trial by Choueiri et al.? https://t.co/x1FzWBiasr #MedEd #MedTwitter pic.twitter.com/w4sns1ifLG

— NEJM Resident 360 (@NEJMres360) May 16, 2023